

# Robert K Stuart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1220782/publications.pdf>

Version: 2024-02-01

136  
papers

5,965  
citations

126907

33  
h-index

74163

75  
g-index

136  
all docs

136  
docs citations

136  
times ranked

7051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.. Journal of Clinical Oncology, 2022, 40, 7031-7031.	1.6	1
2	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology,the, 2021, 8, e481-e491.	4.6	92
3	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Advances, 2021, 5, 2775-2787.	5.2	15
4	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphomaâ€“type Richter syndrome. Blood Advances, 2021, 5, 3528-3539.	5.2	24
5	Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results. Blood, 2021, 138, 2316-2316.	1.4	0
6	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 631-640.	1.3	15
7	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology, 2020, 38, 353-362.	1.7	14
8	Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.. Journal of Clinical Oncology, 2020, 38, 7510-7510.	1.6	16
9	Comparative Analysis of Calcineurin Inhibitorâ€“Based Methotrexate and Mycophenolate Mofetilâ€“Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
10	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 2019, 3, 508-518.	5.2	62
11	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 2019, 85, 106197.	0.8	16
12	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	27.0	796
13	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1744-1755.	2.0	10
14	A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemotherapy and Pharmacology, 2019, 84, 163-173.	2.3	10
15	Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (â‰¥65 Years) AML Patients. Blood, 2019, 134, 832-832.	1.4	47
16	The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia. Blood, 2019, 134, 180-180.	1.4	4
17	A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2019, 37, 7001-7001.	1.6	10
18	Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).. Journal of Clinical Oncology, 2019, 37, 7042-7042.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Outcomes of AML Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation with Adverse Risk Disease By European Leukemianet Classification: A Single Center Retrospective Analysis. <i>Blood</i> , 2019, 134, 5723-5723.	1.4	0
20	A Phase 1 Trial of CNDO-109â€“Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1581-1589.	2.0	50
21	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
22	Phase 3 results for vosaroxin/cytarabine in the subset of patients â‰¥60 years old with refractory/early relapsed acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e514-e518.	3.5	9
23	Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study. <i>Blood</i> , 2018, 132, 1425-1425.	1.4	8
24	The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML. <i>Blood</i> , 2018, 132, 2706-2706.	1.4	1
25	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7040-7040.	1.6	0
26	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1â€“2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402
27	Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 185-195.	2.5	7
28	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2017, 130, 725-725.	1.4	14
29	Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7035-7035.	1.6	14
30	Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7036-7036.	1.6	3
31	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	17.0	20
32	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	1.4	35
33	A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States. <i>Blood</i> , 2016, 128, 1622-1622.	1.4	1
34	Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. <i>Blood</i> , 2016, 128, 902-902.	1.4	15
35	Durable Overall Survival Benefit in Patients â‰¥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial. <i>Blood</i> , 2016, 128, 903-903.	1.4	6
36	Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial. <i>Blood</i> , 2016, 128, 906-906.	1.4	16

#	ARTICLE	IF	CITATIONS
37	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Journal of Clinical Oncology, 2016, 34, 7000-7000.	1.6	130
38	A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States. Blood, 2016, 128, 2793-2793.	1.4	1
39	A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica, 2015, 100, 231-237.	3.5	29
40	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125, 1367-1376.	1.4	747
41	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia and Lymphoma, 2015, 56, 2569-2578.	1.3	36
42	Elevation of c-MYC Disrupts HLA Class II-Mediated Immune Recognition of Human B Cell Tumors. Journal of Immunology, 2015, 194, 1434-1445.	0.8	37
43	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
44	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 1252-1257.	1.6	57
45	<sc>REVEAL</sc>â€, a phase 2 dose regimen optimization study of vosaroxin in older poorâ€risk patients with previously untreated acute myeloid leukaemia. British Journal of Haematology, 2015, 168, 796-805.	2.5	27
46	CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia. Blood, 2015, 126, 2510-2510.	1.4	7
47	Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study. Blood, 2015, 126, 2560-2560.	1.4	1
48	Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. Blood, 2015, 126, 321-321.	1.4	19
49	Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA. Blood, 2015, 126, 3779-3779.	1.4	5
50	Pegfilgrastim 6 Mg Versus 12 Mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: Efficacy, Safety, and Cost Analysis. Blood, 2015, 126, 4306-4306.	1.4	1
51	Allogeneic hematopoietic cell transplant (HCT) in patients (pts) â€ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.. Journal of Clinical Oncology, 2015, 33, 7055-7055.	1.6	0
52	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. Blood, 2015, 126, 2553-2553.	1.4	0
53	Phase I Trial of Bortezomib (PS-341; NSC 681239) and â€Nonhybridâ€ (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical Cancer Research, 2014, 20, 5652-5662.	7.0	26
54	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. Biology of Blood and Marrow Transplantation, 2014, 20, 222-228.	2.0	36

#	ARTICLE	IF	CITATIONS
55	Similar dynamics of intraapheresis autologous <sc>CD</sc>34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion, 2014, 54, 3131-3137.	1.6	4
56	Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. Blood, 2014, 124, 2320-2320.	1.4	5
57	Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR). Blood, 2014, 124, LBA-6-LBA-6.	1.4	14
58	Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience. Blood, 2014, 124, 5907-5907.	1.4	0
59	Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?. Current Hematologic Malignancy Reports, 2013, 8, 156-162.	2.3	7
60	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 2013, 121, 4854-4860.	1.4	546
61	Sphingolipids As a Novel Target For The Treatment Of Multiple Myeloma. Blood, 2013, 122, 3163-3163.	1.4	1
62	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
63	Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor. Blood, 2013, 122, 904-904.	1.4	0
64	Growth factor plus preemptive (â€˜just-in-timeâ€™) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplantation, 2012, 47, 1403-1408.	2.4	45
65	Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. European Journal of Haematology, 2012, 89, 432-434.	2.2	9
66	Vosaroxin: a novel antineoplastic quinolone. Expert Opinion on Investigational Drugs, 2012, 21, 1223-1233.	4.1	30
67	Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leukemia and Lymphoma, 2012, 53, 2444-2448.	1.3	8
68	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. Journal of Clinical Oncology, 2012, 30, 2492-2499.	1.6	165
69	Pegfilgrastimâ€versus filgrastimâ€based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion, 2012, 52, 2375-2381.	1.6	27
70	Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3933-3933.	1.4	2
71	VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2012, 30, TPS6637-TPS6637.	1.6	1
72	Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America. Blood, 2012, 120, 813-813.	1.4	0

#	ARTICLE	IF	CITATIONS
73	The Influence of Race and ADAMTS13 Status On Outcomes in Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2012, 120, 4638-4638.	1.4	0
74	Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus-associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1176-1181.	2.0	76
75	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
76	Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide) on CD34+100 hematopoietic graft function. <i>Transfusion</i> , 2011, 51, 1995-2000.	1.6	26
77	Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. <i>Bone Marrow Transplantation</i> , 2011, 46, 64-69.	2.4	124
78	Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. <i>American Journal of Hematology</i> , 2011, 86, 699-701.	4.1	8
79	A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias. <i>Clinical Cancer Research</i> , 2011, 17, 1140-1146.	7.0	31
80	Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. <i>Blood</i> , 2011, 117, 5941-5952.	1.4	101
81	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. <i>Clinical Cancer Research</i> , 2011, 17, 3388-3397.	7.0	49
82	Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. <i>Bone Marrow Transplantation</i> , 2011, 46, 523-528.	2.4	70
83	Comparison Between Pegfilgrastim and Filgrastim-Based Autologous Hematopoietic Stem Cell Mobilization in the Setting of Patient Adapted (Just in Time) Plerixafor: Efficacy and Cost Analysis. <i>Blood</i> , 2011, 118, 1921-1921.	1.4	1
84	Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. <i>Blood</i> , 2011, 118, 2520-2520.	1.4	2
85	Potential Use of Sphingosine Kinase-2 Selective Inhibitors for the Treatment of Multiple Myeloma. <i>Blood</i> , 2011, 118, 5105-5105.	1.4	0
86	Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2909-2909.	1.4	0
87	Regulation and Functional Role of Beta2-Adrenergic Receptor in Acute Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 2563-2563.	1.4	0
88	Helical tomotherapy for extramedullary hematopoiesis involving the pericardium in a patient with chronic myeloid leukemia. <i>Japanese Journal of Radiology</i> , 2010, 28, 476-478.	2.4	4
89	Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. <i>American Journal of Hematology</i> , 2010, 85, 627-629.	4.1	10
90	Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: A unique case and review of the literature. <i>Leukemia Research</i> , 2010, 34, 1543-1544.	0.8	9



#	ARTICLE	IF	CITATIONS
91	Overcoming HLA-DRB1 donor specific antibody-mediated haematopoietic graft failure. British Journal of Haematology, 2010, 151, 94-96.	2.5	21
92	Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. British Journal of Haematology, 2010, 151, 430-434.	2.5	57
93	Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 815-821.	1.6	70
94	Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside. Expert Opinion on Investigational Drugs, 2010, 19, 427-436.	4.1	72
95	Most Patients with Core Binding Factor AML Require Hematopoietic Stem Cell Transplantation for Long-Term Survival: Long Term Follow-up of a Cohort of Unselected Patients.. Blood, 2010, 116, 4560-4560.	1.4	12
96	Dual Inhibition of mTOR and Pim Kinase Pathways Using Small Molecule Inhibitors Synergistically Kills Myeloid Leukemic Cells In Vitro and In Vivo.. Blood, 2010, 116, 293-293.	1.4	0
97	Extended Use of Ciprofloxacin Markedly Decreases the Incidence of Severe BK Virus-Associated Hemorrhagic Cystitis In Allogeneic HSCT Recipients. Blood, 2010, 116, 2317-2317.	1.4	0
98	Association of Age with Fluorescence In Situ Hybriditization (FISH) Abnormalities In Multiple Myeloma Patients Reveals Higher Rate of Igh Translocations Among Older Patients. Blood, 2010, 116, 1913-1913.	1.4	0
99	Amrubicin Targets Nuclear Matrix-Bound Topoisomerase II In Human Myeloid Leukemia Cells. Blood, 2010, 116, 1830-1830.	1.4	0
100	Effects of Method of Peripheral Blood Hematopoietic Stem Cell Mobilization (G-CSF, G-CSF +) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Comparison Across Cohorts with Similar CD34+ Cell Dose. Blood, 2010, 116, 2255-2255.	1.4	0
101	High-Dose Cyclophosphamide Is An Effective Salvage Therapy for High-Risk Multiple Myeloma Refractory to New Biological Agents. Blood, 2010, 116, 5041-5041.	1.4	0
102	Race, Access to Care, and Outcome After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2010, 116, 1509-1509.	1.4	0
103	Extensive Involvement of the Gastrointestinal Tract by a de novo Presentation of the Monoblastic Type of Myeloid Sarcoma: A Case Report of a Rare Entity That is Often Misdiagnosed. American Journal of the Medical Sciences, 2009, 338, 513-516.	1.1	7
104	Hematopoietic stem cell origin of human fibroblasts: Cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Experimental Hematology, 2009, 37, 1464-1471.	0.4	20
105	Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. American Journal of Hematology, 2009, 84, 535-537.	4.1	10
106	Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head and Neck, 2009, 31, 493-502.	2.0	31
107	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood, 2009, 114, 4027-4033.	1.4	52
108	A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.. Blood, 2009, 114, 1037-1037.	1.4	3

#	ARTICLE	IF	CITATIONS
109	Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.. Blood, 2009, 114, 3094-3094.	1.4	4
110	Cost-Effective Use of Plerixafor for Hematopoietic Stem Cells Mobilization: Development and Validation of a Decision-Making Algorithm.. Blood, 2009, 114, 3216-3216.	1.4	8
111	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. Blood, 2009, 114, 788-788.	1.4	17
112	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.. Blood, 2009, 114, 790-790.	1.4	124
113	Excessive Rate of Late Infections and Treatment Related Mortality Associated with the Use of Alemtuzumab in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Trial.. Blood, 2009, 114, 2230-2230.	1.4	0
114	Tetraploidy and 5q deletion in myelodysplastic syndrome: A case report. Cancer Genetics and Cytogenetics, 2008, 183, 64-68.	1.0	5
115	Defects in HLA class II antigen presentation in B-cell lymphomas. Leukemia and Lymphoma, 2008, 49, 353-355.	1.3	19
116	Proximal Esophageal Stenosis in Head and Neck Cancer Patients after Total Laryngectomy and Radiation. Orl, 2008, 70, 229-235.	1.1	36
117	Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.. Blood, 2008, 112, 1573-1573.	1.4	3
118	Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood, 2007, 109, 3069-3075.	1.4	209
119	Posttransplantation lymphoproliferative disorderâ€™The great mimic in liver transplantation: Appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transplantation, 2007, 13, 904-912.	2.4	57
120	Jumping translocation of 1q in BCR/ABL-positive acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2007, 172, 90-91.	1.0	6
121	Activity and Mechanism of Action of AS1411 in Acute Myeloid Leukemia Cells.. Blood, 2007, 110, 1604-1604.	1.4	7
122	Imidazoacridinones Are Bifunctional Targeting Agents Active in Leukemia Cells.. Blood, 2006, 108, 2323-2323.	1.4	0
123	Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.. Blood, 2005, 106, 3338-3338.	1.4	2
124	Increased Stability of Bcl-2 mRNA in B-Cell Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 4789-4789.	1.4	0
125	Immunotherapy of Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology, 2001, 2, 209-215.	1.6	5
126	Localized non-Hodgkin's lymphoma of Waldeyer's ring: Clinical features, management, and prognosis of 130 adult patients. Head and Neck, 2001, 23, 547-558.	2.0	99



#	ARTICLE	IF	CITATIONS
127	High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Research and Treatment, 2000, 62, 237-244.	2.5	19
128	Malignant Ovarian Germ Cell Tumours: A Survival and Prognostic Analysis. Acta Oncol <sup>3</sup> gica, 1999, 38, 455-460.	1.8	20
129	Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 95-103.	1.1	68
130	Breast cancer in the eastern province of Saudi Arabia. Medical Oncology and Tumor Pharmacotherapy, 1998, 15, 241-247.	1.1	32
131	Cancer Chemotherapy and Biological Response Modifiers, Annual 17 Cancer Chemotherapy and Biological Response Modifiers, Annual 17 Edited by H.M.Pinedo, D.L.Longo and B.A.Chabner. Available from: Elsevier Science BV, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, or Elsevier Science Inc., P.O. Box 945, Madison Square Station, New York NY 10160-0757, USA. Price: US\$185.00. ISBN 0-444-82671-8.. Annals of Saudi Medicine, 1998, 18, 373-373.	1.1	0
132	Disposition of folic acid and its metabolites: A comparison with leucovorin. Clinical Pharmacology and Therapeutics, 1994, 55, 501-508.	4.7	24
133	G-CSF improves granulocytopenia in Felty's syndrome without flare-up of arthritis. American Journal of Hematology, 1993, 42, 230-231.	4.1	11
134	Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemotherapy and Pharmacology, 1990, 26, 397-402.	2.3	8
135	Synergism between 4-hydroperoxycyclophosphamide and cisplatin: importance of incubation sequence and measurement of cisplatin accumulation. Biochemical Pharmacology, 1990, 39, 607-609.	4.4	0
136	In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. Cancer Chemotherapy and Pharmacology, 1989, 23, 129-34.	2.3	7